Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study

Ullah, Irfan; Shah, Aamer Ali; Basit, Anila; Ali, Mazhar; Khan, Abdul Aziz; Ullah, Ubaid; Ihtesham, Muhammad; Mehreen, Sumaira; Mughal, Anita; Javaid, Arshad

doi:10.1186/s12879-016-1745-2

Cited by 49 publications

(57 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…World health organization (WHO) endorsed Xpert® MTB/RIF assay for the diagnosis of Mycobacterium tuberculosis (MTB) and the mutations that confer Rifampicin resistance (RR) [1]. This assay has revolutionized the diagnosis of TB by simultaneously detecting the bacteria and RR [2,3], which is a surrogate marker for MDR-TB [2,4]. RR is determined based on mutations in the 81 bp (codons 507-533) regions of the β-subunit of the RNA polymerase enzyme (rpoB) gene using five overlapping probes [3,5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia

et al. 2020

View full text Add to dashboard Cite

Background: Xpert® MTB/RIF assay is currently used in Ethiopia for the rapid diagnosis of Mycobacterium tuberculosis (MTB) and mutations that confer Rifampicin resistance. Rifampicin resistance is determined based on any mutation in the 81 bp of rpoB gene using five overlapping probes represented as Probe A (codons 507-511), Probe B (codons 512-518), Probe C (codons 518-523), Probe D (codons 523-529) and Probe E (codons 529-533). In this review, we assessed the frequency of missed probe types for Rifampicin Resistance results. Methods: Data were reviewed from specimens received and tested using Xpert® MTB/RIF assay at Ethiopian National Tuberculosis Reference Laboratory, in Addis Ababa from 15 July 2016 to 31 December 2018 retrospectively. All archived data were reviewed carefully to describe missed probe types and the quantity of DNA in the sample. Results: A total of 100 specimens were reported as MTB Detected Rifampicin Resistance Detected by Xpert® MTB/RIF assay. More than half (55%) of these results were reported from male patients. The median age was 28.0 years (5 months to 88 years). Majorities (62%) of the cases were detected from sputum. Among the total of 38 extrapulmonary samples, lymph node aspirates were accounted for 50% (19/38). The most common mutations (81.0%) were found in the Probe E region followed by Probe D (10.0%), and Probe B (3.0%). Mutations in Probe A and Probe C regions were not observed. However, six (6.0%) Rifampicin resistance cases were found without any missed probe type. The delta Ct max is ≥4.3. No specimen yielded Rifampicin resistance associated with more than one probe failure or mutation combinations. Conclusion: Mutations associated with Probe E (codons 529-533) region were identified as the commonest rpoB gene mutations. The Rifampicin resistance results found without any identified missing probe needs further study. The lower DNA amount was observed in extrapulmonary specimens compared with sputum.

show abstract

Section: Introductionmentioning

confidence: 99%

“…These probes are named as Probe A (codons 507-511), Probe B (codons 511-518), Probe C (codons 518-523), Probe D (codons 523-529) and Probe E (codons 529-533) [3,5]. A mutation in these regions accounts for more than 95% of RR [3,4].…”

Section: Introductionmentioning

confidence: 99%

Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The emergence and spread of drug-resistant MTB strain largely associated with inadequate treatment. MDR-TB is caused by MTB that is resistant to at least two of the most powerful first-line anti-TB drugs, isoniazid (INH), and rifampicin (RIF) [3,4]. It was estimated that from 480,000 new cases of MDR-TB in the worldwide, about 9% of them were advanced to extensively drug-resistant TB (XDR-TB) and approximately 190, 000 were dead [2,[5][6].…”

Section: Introductionmentioning

confidence: 99%

Rifampicin resistant tuberculosis in presumptive pulmonary tuberculosis cases in Dubti Hospital, Afar, Ethiopia

Gebrehiwet

Kahsay

Welekidan

et al. 2019

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Ethiopia stood third in drug-resistant tuberculosis (TB) in Africa, and more than 5,000 MDR-TB patients are reported each year. Greater than 90% of rifampicin (RIF) resistant strains are resistant to isoniazid (INH) and hence the objective of this study was to determine the prevalence and risk factors of RIF resistant MTB among presumptive TB cases at Dubti General Hospital, Afar, Ethiopia. Methodology: In this cross-sectional study, 384 presumptive TB cases were recruited and a structured questionnaire was used to collect socio-demographic and clinical data. Sputum samples were collected and examined using X-pertMTB/RIF assay. Bivariate, multivariate logistic regressions, and fishers' exact analysis were done to assess the associations between the prevalence of TB and MDR-TB with different socio-demographic and clinical variables. Results: In the present study, the overall prevalence of pulmonary TB was 24.5% (94/384), of this 4 (4.3%) isolates were resistant to RIF. History of anti-TB treatment (AOR = 2.4, 95% CI: 1.3-4.4 and TB contact (AOR = 3.6, 95% CI: 2.1-6.2 were significantly associated with gene X-pert MTB/RIF positive TB. Moreover, resistance to rifampicin was statistically associated with the history of TB contact with multi-drug resistant TB (P = 0.027) and khat chewer cases (P = 0.04). Conclusions: The overall prevalence of TB and its drug-resistant were relatively higher than that of in the general population in Ethiopia. History of anti-TB treatment and TB contact were significantly associated with X-pert MTB/RIF positive MDR-TB.

show abstract

“…Another study in Khyber Pakhtoonkhwa, Pakistan found that Probe E mutation was the most common rpoB genetic mutation (77%). 13 However, they also found less common mutations in Probe B (10.8%), D (8.3%), A (1.2%), and C (1.5%). Similarly, in China reported mutations were in codons 531 (41%), 526 (40%), and 513 (4%) in 81-bp.…”

Section: Discussionmentioning

confidence: 93%

Mycobacterium Tuberculosis;

Siddique¹,

Shafee²,

Abbas³

et al. 2019

TPMJ

View full text Add to dashboard Cite

Objectives: The primary objective of this study is to determine the frequency of rpoB gene mutations within 81-bp RRDR in isolates from Quetta, Pakistan using GeneXpert® MTB/RIF assay. Background: Multi drug resistance is one of the major obstacles in the control of tuberculosis throughout the globe. Study Design: A cross sectional experimental study was designed. Setting: A total of 500 clinical specimens obtained from suspected TB patients at Provincial TB Reference Laboratory, Fatima Jinnah General and Chest Hospital Quetta, Pakistan Period: From January to July 2017. Methodology: Were analyzed by GeneXpert® MTB/RIF assay. Statistical analysis of the data was performed using SPSS version 20. Results: Out of total 500 samples, MTB was detected in 211 (42%) cases by GeneXpert® MTB/RIF assay [positive pulmonary cases 48.8% (206/422) and extra-pulmonary 6.4% (5/78)]. Among 211 MTB positive cases, the assay detected 11 (5.2%) cases with RIF-resistance caused by various rpoB gene mutations within 81-bp RRDR. All the eleven RIF-resistant isolates were found to have mutations only in Probe E and none of cases had RIF-resistance associated with probes A, B, C, and D. Out of 11 RRD cases, 4 (2%) were males and 7 (3.3%) were females. New TB cases were 3 (1.4%) and previously treated cases were 8 (3.8%). Conclusion: In our settings 11/211 (5.2%) of the TB patients showed rifampicin resistance. Probe E mutations (also called codons 531 and 533) were the only rpoB gene mutations detected by GeneXpert® MTB/RIF assay. No mutations were detected in the codons 511, 513, 516, 518, 522 and 526 sequences.

show abstract

Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study

Cited by 49 publications

References 25 publications

Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia

Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia

Rifampicin resistant tuberculosis in presumptive pulmonary tuberculosis cases in Dubti Hospital, Afar, Ethiopia

Mycobacterium Tuberculosis;

Contact Info

Product

Resources

About